News by Industry

Biotechnology

Releases published in the last 30 days.

Page 1 of 1

Solvay expands Hydrogen Peroxide grade production in the Netherlands for the pharmaceutical industry to meet growing demand
1/23/2015 1:13:14 PM
Solvay will build a new manufacturing and filling facility in the Netherlands to produce Hydrogen Peroxide grades that are used as disinfection and decontamination agents to meet growing demand from the pharmaceutical industry.The new facility at Solvay’s Peroxide production site in Linne-Herten, in the southern part of the Netherlands, is due to be completed in July 2015 and …
FUJIFILM Diosynth Biotechnologies Breaks Ground on Laboratory Facility in Research Triangle Park, NC
1/23/2015 11:47:40 AM
January 23, 2015 –  FUJIFILM Diosynth Biotechnologies U.S.A., Inc. , a Biologics Contract Development and Manufacturing Organization with experience focused on the development and manufacture of recombinant biopharmaceuticals including proteins, vaccines, and monoclonal antibodies,broke ground this week to launch the construction of a new three-story, 62,000 square foot …
Pennsylvania Company Releases New Cold Storage And Monitoring Solution To Meet CDC Vaccine Storage Requirements
Pennsylvania Company Releases New Cold Storage And Monitoring Solution To Meet CDC Vaccine Storage Requirements
1/19/2015 4:26:13 PM
The Aegis MD-14 is an affordable state-of-the-art cold storage environment which meets and exceeds Centers for Disease Control (CDC/VFC) regulations for vaccine storage and handling.  A compact unit, the Aegis MD-14 is an ideal solution for single station or low volume applications and is available in a variety of sizes to meet your storage needs.  The MD-14 is …
Addex and Dystonia Medical Research Foundation Announce Partnership to Explore the Therapeutic use of Dipraglurant in the Treatment of Dystonia
1/19/2015 10:46:01 AM
Addex Therapeutics (SIX: ADXN), a leading company pioneering allosteric modulation-based drug discovery and development and the Dystonia Medical Research Foundation (DMRF) announced today entering a collaboration to explore the use of dipraglurant to treat dystonia, the third most common movement disorder following essential tremor and Parkinson’s disease. Dipraglurant, a …
Roche acquires Trophos to expand portfolio in neuromuscular disease with high medical need
1/16/2015 9:37:23 AM
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that it has agreed to acquire Trophos, a privately held biotechnology company based in Marseille, France. Trophos’s proprietary screening platform generated olesoxime (TRO19622), which is being developed for SMA – a rare and debilitating genetic neuromuscular disease that is most commonly diagnosed in children. Results from a …
Dako, an Agilent Technologies Company, and Cell Signaling Technology Announce Partnership Within Companion Diagnostics
1/12/2015 5:46:22 PM
Dako, an Agilent Technologies company and a worldwide provider of cancer diagnostics, and Cell Signaling Technology (CST), a worldwide provider of antibodies, today announced that they have entered into a strategic partnership to supply antibodies for use in Dako-branded companion diagnostics products. "We are pleased to work with CST in the development of high-quality, …
MedImmune enters licensing agreement with Omnis Pharmaceuticals for oncolytic viruses in immuno-oncology
1/12/2015 12:39:00 PM
AstraZeneca today announced that MedImmune, its global biologics research and development arm, has entered into a licensing agreement with Omnis Pharmaceuticals (Omnis), a privately-held biotechnology company focused on the development of oncolytic viruses. This agreement will allow MedImmune to combine key agents from its investigational immunotherapy portfolio with Omnis’ …
Roche enters a broad strategic collaboration with Foundation Medicine in the field of molecular information in oncology
1/12/2015 12:12:26 PM
Roche to acquire a majority interest in Foundation Medicine (FMI) of up to 56.3% on a fully diluted basis through a tender and acquisition of newly issued shares. Roche will tender for approximately 15.6 million Foundation Medicine shares at USD 50 per share with an aggregate tender value of approximately USD 780 million. Roche will also invest USD 250 million in …
FDA approves anti-clotting drug Savaysa
1/9/2015 11:44:07 AM
The U.S. Food and Drug Administration today approved the anti-clotting drug Savaysa (edoxaban tablets) to reduce the risk of stroke and dangerous blood clots (systemic embolism) in patients with atrial fibrillation that is not caused by a heart valve problem. Atrial fibrillation is one of the most common types of abnormal heart rhythm. It occurs when the heart’s two upper …
Medtronic-Sponsored European Clinical Trial to Evaluate Cryoballoon Ablation as First-Line Treatment for Patients with Symptomatic Paroxysmal Atrial Fibrillation
1/8/2015 9:47:50 AM
Medtronic, Inc., (NYSE:MDT) today announced the initiation of a randomized clinical trial in Europe to assess the benefits of ablation using the Medtronic Artic Front Advance(TM) cryoballoon as a first-line treatment for atrial fibrillation (AF) patients. While medication is currently considered first-line treatment for AF, clinical research indicates that half of all …
Publicis Touchpoint Solutions Partners with Cegedim Relationship Management for Next-Generation CRM, CLM, and Remote Detailing Solution
1/6/2015 12:00:00 PM
  Yardley, PA — January 6, 2015 —  Publicis Touchpoint Solutions , Inc.—a leading provider of customized cross-channel healthcare sales, service, and clinical teams—announced today that it has entered into a strategic partnership with Cegedim Relationship Management . Touchpoint will be employing Cegedim’s cloud-based customer relationship management (CRM), closed loop …
Medical Information Records, LLC, Developer of AnesthesiaOSTM, Signs Technology Partnership Agreement with Dell Products L.P.
1/5/2015 7:00:00 AM
 MIR and Dell are working to certify MIR’s flagship product AnesthesiaOSTM on the Dell VRTX Server, Dell Venue Tablets, Dell Boomi, and Dell Statistica. 1.     Dell PowerEdge VRTX integrates servers, storage, networking and management in a compact shared infrastructure optimized for office environments.   2.     Dell Venue Tablets   are powerful and stylish …
Bad Luck of Random Mutations Plays Predominant Role in Cancer, Study Shows
Bad Luck of Random Mutations Plays Predominant Role in Cancer, Study Shows
1/2/2015 11:35:44 AM
Scientists from the Johns Hopkins Kimmel Cancer Center have created a statistical model that measures the proportion of cancer incidence, across many tissue types, caused mainly by random mutations that occur when stem cells divide. By their measure, two-thirds of adult cancer incidence across tissues can be explained primarily by “bad luck,” when these random mutations occur …
Stem cell transplants may halt progression of multiple sclerosis
12/31/2014 12:52:19 PM
Three-year outcomes from an ongoing clinical trial suggest that high-dose immunosuppressive therapy followed by transplantation of a person’s own blood-forming stem cells may induce sustained remission in some people with relapsing-remitting multiple sclerosis (RRMS). RRMS is the most common form of MS, a progressive autoimmune disease in which the immune system attacks the …
H2: The World’s First Wearable High Blood Pressure Monitor Exceeds 
$50K Indiegogo Campaign Goal and Will Donate 5% to The American Heart Association
H2: The World’s First Wearable High Blood Pressure Monitor Exceeds $50K Indiegogo Campaign Goal and Will Donate 5% to The American Heart Association
12/31/2014 11:58:26 AM
(SAN JOSE, CA) The H2 , the first wearable Blood Pressure Monitor, recently closed a successful Indiegogo campaign exceeding its $50,000 goal by 101%. The Indiegogo funds will enable the company to manufacture and distribute the product in the U.S. The company will be donating 5% of the total funds to the American Heart Association to commemorate the success of the …
The protein GRP78 identified as a possible universal therapeutic target for multiple viral and bacterial infections, including Ebola, Influenza and Hepatitis and brain cancer
12/29/2014 11:13:01 AM
A protein called GRP78 could be a universal therapeutic target for treating human diseases like brain cancer, Ebola, Influenza, Hepatitis and superbug bacteria such as MRSE and MRSA , according to a Virginia Commonwealth University-led pre-clinical study published this month in the Journal of Cellular Physiology. By using a drug combination of the clinically tested …

  • « Previous
  • 1
  • Next »